688235 百济神州
已收盘 02-27 15:00:01
资讯
新帖
简况
核心产品全球销售280亿，百济神州结束10年亏损长跑
观察者网 · 15:15
核心产品全球销售280亿，百济神州结束10年亏损长跑
首度盈利，股价为何崩了？百济神州叫好不叫座的“盈利魔咒”
华夏时报网 · 13:21
首度盈利，股价为何崩了？百济神州叫好不叫座的“盈利魔咒”
百济神州迎来“幸福的烦恼” 公司全球研发负责人汪来：“牌”多的时候，不见得每一张都得自己打
每日经济新闻 · 02-27 21:19
百济神州迎来“幸福的烦恼” 公司全球研发负责人汪来：“牌”多的时候，不见得每一张都得自己打
首度全年盈利的百济神州，与川股百利天恒有一个共同点：都被这些公募基金重仓
金融投资报 · 02-27 16:51
首度全年盈利的百济神州，与川股百利天恒有一个共同点：都被这些公募基金重仓
群益证券：维持百济神州(06160)“买入”的评级 首年实现盈利且商业化效果显现
智通财经 · 02-27 14:28
群益证券：维持百济神州(06160)“买入”的评级 首年实现盈利且商业化效果显现
海通国际：维持百济神州“优于大市”评级 26年收入利润有望稳步提升
智通财经 · 02-27 13:56
海通国际：维持百济神州“优于大市”评级 26年收入利润有望稳步提升
百济神州穿越“死亡谷”：首次实现全年盈利 下一波增长点在哪？
21世纪经济报道 · 02-27 10:27
百济神州穿越“死亡谷”：首次实现全年盈利 下一波增长点在哪？
扭亏为盈！4000亿市值A股公司百济神州，最新发布
每日经济新闻 · 02-26 20:52
扭亏为盈！4000亿市值A股公司百济神州，最新发布
百济神州预计2026年营业收入436亿元至450亿元
北京商报 · 02-26 20:23
百济神州预计2026年营业收入436亿元至450亿元
百济神州(06160)2025年业绩强劲增长 经调整净利润约9.18亿美元 同比扭亏为盈
智通财经 · 02-26 19:15
百济神州(06160)2025年业绩强劲增长 经调整净利润约9.18亿美元 同比扭亏为盈
百济神州公布2025年第四季度及全年财报 彰显百悦泽全球佳绩与肿瘤学领导地位
美股速递 · 02-26 19:04
百济神州公布2025年第四季度及全年财报 彰显百悦泽全球佳绩与肿瘤学领导地位
百济神州跌5.65% 东莞证券等在其历史最高点唱多
中国经济网 · 02-26 17:05
百济神州跌5.65% 东莞证券等在其历史最高点唱多
什么情况？百济神州绩前挫逾6%！港股通创新药ETF（520880）、港股通医疗ETF（159137）跌近3%
新浪基金 · 02-26 15:01
什么情况？百济神州绩前挫逾6%！港股通创新药ETF（520880）、港股通医疗ETF（159137）跌近3%
百济神州皮下注射剂型获临床试验许可，将发布2025年业绩
经济观察网 · 02-14
百济神州皮下注射剂型获临床试验许可，将发布2025年业绩
百济神州2025年财报发布及电话会议安排公布
经济观察网 · 02-13
百济神州2025年财报发布及电话会议安排公布
百济神州：公司会在定期报告中面向所有投资者统一披露截至相应报告期末的股东户数
证券日报 · 02-09
百济神州：公司会在定期报告中面向所有投资者统一披露截至相应报告期末的股东户数
每周股票复盘：百济神州（688235）1月31日已发行股1,425,622,549股
证券之星 · 02-08
每周股票复盘：百济神州（688235）1月31日已发行股1,425,622,549股
美股内部交易 | 百济神州于2月6日披露5笔公司内部人交易情况
同花顺iNews · 02-07
美股内部交易 | 百济神州于2月6日披露5笔公司内部人交易情况
百济神州（688235）披露证券变动月报表，2月5日股价下跌0.73%
证券之星 · 02-05
百济神州（688235）披露证券变动月报表，2月5日股价下跌0.73%
每周股票复盘：百济神州（688235）授出273,442股普通股受限制股份单位
证券之星 · 02-01
每周股票复盘：百济神州（688235）授出273,442股普通股受限制股份单位
加载更多
公司概况
公司名称：
百济神州有限公司
所属行业：
医药制造业
上市日期：
2021-12-15
主营业务：
百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。
发行价格：
192.60
{"stockData":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":257.7,"timestamp":1772175601000,"preClose":263.44,"halted":0,"volume":3172136,"delay":0,"changeRate":-0.0218,"floatShares":114999999,"shares":1541000000,"eps":-0.0994,"marketStatus":"已收盘","change":-5.74,"latestTime":"02-27 15:00:01","open":258.33,"high":262.39,"low":251,"amount":819000000,"amplitude":0.0432,"askPrice":257.7,"askSize":25,"bidPrice":257.69,"bidSize":3,"shortable":0,"etf":0,"ttmEps":-0.0994,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772415000000},"marketStatusCode":5,"adr":0,"adjPreClose":263.44,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772155800000,1772163000000],[1772168400000,1772175600000]],"highLimit":289.78,"lowLimit":237.1,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1540677809,"isCdr":false,"pbRate":13.53,"roa":"--","roe":"4.26%","epsLYR":-3.64,"committee":0.415929,"marketValue":397033000000,"turnoverRate":0.0276,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-03-02。","afterMarket":{"amount":0,"volume":0,"close":257.7,"buyVolume":321,"sellVolume":0,"time":1772177637558,"indexStatus":"已收盘 02-27 15:30:00","preClose":263.44},"hkstockBrief":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":192.3,"timestamp":1772179700007,"preClose":194.4,"halted":0,"volume":5930951,"delay":0,"premium":"-34.52"},"floatMarketCap":29650000000},"requestUrl":"/m/hq/s/688235","defaultTab":"news","newsList":[{"id":"2614188608","title":"核心产品全球销售280亿，百济神州结束10年亏损长跑","url":"https://stock-news.laohu8.com/highlight/detail?id=2614188608","media":"观察者网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614188608?lang=zh_cn&edition=full","pubTime":"2026-02-28 15:15","pubTimestamp":1772262900,"startTime":"0","endTime":"0","summary":"2月26日，百济神州发布2025年度业绩快报，公司成立以来首次实现年度盈利。数据显示，全年营业总收入382.05亿元，同比增长40.4%；归属于母公司所有者的净利润14.22亿元，较上年同期净亏损49. ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260228/c674988359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2614789759","title":"首度盈利，股价为何崩了？百济神州叫好不叫座的“盈利魔咒”","url":"https://stock-news.laohu8.com/highlight/detail?id=2614789759","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614789759?lang=zh_cn&edition=full","pubTime":"2026-02-28 13:21","pubTimestamp":1772256083,"startTime":"0","endTime":"0","summary":"2025年，对于素有“创新药一哥”之称的百济神州而言，无疑是载入史册的一年。这份由公司于2月26日晚间交出的年度成绩单，在“归属于母公司所有者的净利润”这一关键指标上，终于迎来了期盼已久的正向数字——14.22亿元。从长达数年的巨额亏损到首次全年盈利，从单纯“烧钱”研发到初步实现自我“造血”，百济神州似乎终于迎来了宣扬已久的“商业化元年”的曙光。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602283657400898.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602283657400898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1161","LU1969619763.USD","LU1719994722.HKD","ONC","BK1588","LU1303224171.USD","LU0588546209.SGD","BK4585","BK4139","LU1251922891.USD","06160","BK4526","BK1583","LU0307460666.USD","LU2328871848.SGD","688235","BK1500","BK4588","LU1770034418.SGD"],"gpt_icon":0},{"id":"2614856787","title":"百济神州迎来“幸福的烦恼” 公司全球研发负责人汪来：“牌”多的时候，不见得每一张都得自己打","url":"https://stock-news.laohu8.com/highlight/detail?id=2614856787","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614856787?lang=zh_cn&edition=full","pubTime":"2026-02-27 21:19","pubTimestamp":1772198372,"startTime":"0","endTime":"0","summary":"“我们现在的痛苦和快乐就是管线太强劲，太强劲了以后我们有很多舍不得。你不能slowdown（放慢速度）了，还得快步地往前跑。这里面的确有一个平衡的问题。”2月27日上午，百济神州在线上召开2025年年度业绩路演小组会，公司总裁兼首席运营官吴晓滨说了这样一段话。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602273656980575.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656980575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1500","BK4588","BK4585","LU1303224171.USD","ONC","BK4139","BK0239","BK4526","BK1161","LU0588546209.SGD","LU1770034418.SGD","LU1251922891.USD","LU2328871848.SGD","LU1969619763.USD","LU1719994722.HKD","688235","LU0307460666.USD","BK1588","06160"],"gpt_icon":0},{"id":"2614083875","title":"首度全年盈利的百济神州，与川股百利天恒有一个共同点：都被这些公募基金重仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2614083875","media":"金融投资报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614083875?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:51","pubTimestamp":1772182279,"startTime":"0","endTime":"0","summary":"金融投资报记者贺梦璐“盈利了，但市值却跌破3000亿元。”这或许是百济神州发布2025年度业绩快报后，留给资本市场的最大困惑。金融投资报记者注意到，当投资者将目光转向其股东名单时，一个有意思的巧合开始浮现：那些重仓百济神州的公募基金，同样也对川股百利天恒青睐有加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656715059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0307460666.USD","91194","LU0588546209.SGD","02615","ONC","LU1770034418.SGD","LU1969619763.USD","BK4139","06160","LU1251922891.USD","LU1303224171.USD","BK4526","BK4585","LU1719994722.HKD","BK1500","BK1583","688235","BK0239","LU2328871848.SGD","688506","BK1161","BK1588","BK4588"],"gpt_icon":0},{"id":"2614860298","title":"群益证券：维持百济神州(06160)“买入”的评级 首年实现盈利且商业化效果显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2614860298","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614860298?lang=zh_cn&edition=full","pubTime":"2026-02-27 14:28","pubTimestamp":1772173726,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，群益证券发布研报称，维持百济神州“买入”的评级。群益证券主要观点如下：公司业绩快报公司发布2025年业绩快报，实现营业总收入382.1亿元，同比增长40.4%，其中产品收入377.7亿元，YOY+39.9%;实现归母净利润14.2亿元，公司业绩符合预期。其中Q4单季度实现营收106.1亿元，YOY+31.3%,录得归母净利润2.8亿元。另外，百泽安销售53亿元,YOY+19%,主要是在中国新适应获批及入院量增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408078.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","ONC","688235","06160"],"gpt_icon":0},{"id":"2614888548","title":"海通国际：维持百济神州“优于大市”评级 26年收入利润有望稳步提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2614888548","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614888548?lang=zh_cn&edition=full","pubTime":"2026-02-27 13:56","pubTimestamp":1772171760,"startTime":"0","endTime":"0","summary":"海通国际发布研报称，维持百济神州(06160)“优于大市”评级，维持FY26/27营收预测64亿/71亿美元，略微调整FY26/27的归母净利润预测至6.1亿/10.4亿美元，该行使用现金流折现(DCF)模型及FY27- ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260227/c674965355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688235"],"gpt_icon":0},{"id":"2614029001","title":"百济神州穿越“死亡谷”：首次实现全年盈利 下一波增长点在哪？","url":"https://stock-news.laohu8.com/highlight/detail?id=2614029001","media":"21世纪经济报道","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614029001?lang=zh_cn&edition=full","pubTime":"2026-02-27 10:27","pubTimestamp":1772159237,"startTime":"0","endTime":"0","summary":"2月26日晚间，百济神州（纳斯达克代码：BGNE；香港联交所代码：06160.HK；上交所代码：688235.SH）发布了其2025年度业绩快报。报告期内，公司营业总收入达382.05亿元，同比增长40.4%。得益于产品收入增长和费用管理推动的经营效率提升，公司归属于母公司所有者的净利润达14.22亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602273656435915.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656435915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1719994722.HKD","LU1770034418.SGD","BK4585","LU0588546209.SGD","BK1588","BK1583","LU1969619763.USD","688235","BK1500","BK1161","LU0307460666.USD","LU1303224171.USD","ONC","BK4588","BK0239","BK4526","06160","LU1251922891.USD","LU2328871848.SGD","BK4139"],"gpt_icon":0},{"id":"2614004445","title":"扭亏为盈！4000亿市值A股公司百济神州，最新发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2614004445","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614004445?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:52","pubTimestamp":1772110320,"startTime":"0","endTime":"0","summary":" 26日，百济神州发布业绩快报，2025年度营业总收入为382.05亿元，同比增长40.4%；归属于母公司所有者的净利润为14.22亿元， 同比扭亏为盈。 2025年，百悦泽全球销售额总计280.67亿元，同比增长48.8%，已在BTK抑制剂领域稳固确立全球领导者的地位。 市场上，截至A股今日收盘，百济神州股价跌5.65%，市值为4058.8亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-02-26/doc-inhpefha7129939.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-26/doc-inhpefha7129939.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK4526","BK1500","06160","ONC","688235","BK4585","BK4588","159982","399300","BK1583","BK1588","LU1969619763.USD","LU0307460666.USD","LU1719994722.HKD","LU1251922891.USD","LU0588546209.SGD","LU1770034418.SGD","LU1303224171.USD","BK0239","LU2328871848.SGD","BK1161"],"gpt_icon":0},{"id":"2614376049","title":"百济神州预计2026年营业收入436亿元至450亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614376049","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614376049?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:23","pubTimestamp":1772108626,"startTime":"0","endTime":"0","summary":"北京商报讯2月26日晚间，百济神州（688235）发布关于2026年度经营业绩预测的公告显示，综合近年来的业务发展趋势，公司预计的中国企业会计准则下2026年营业收入将介于436亿元至450亿元之间，毛利率将为80%区间的高位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602263655573663.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602263655573663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06160","ONC","688235"],"gpt_icon":0},{"id":"2614041010","title":"百济神州(06160)2025年业绩强劲增长 经调整净利润约9.18亿美元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2614041010","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614041010?lang=zh_cn&edition=full","pubTime":"2026-02-26 19:15","pubTimestamp":1772104553,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布公告，2025年第四季度，全球总收入达15亿美元，同比增长33%;全年全球总收入达53亿美元，同比增长40%。2025年第四季度经调整净利润约2.25亿美元，同比增长12.97倍;全年经调整净利润约9.18亿美元，同比扭亏为盈。2025年第四季度，自由现金流为3.8亿美元，比上年同期增加3.97亿美元。2026年全年总收入指引为62亿美元至64亿美元之间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688235","ONC","06160"],"gpt_icon":1},{"id":"1138709636","title":"百济神州公布2025年第四季度及全年财报 彰显百悦泽全球佳绩与肿瘤学领导地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1138709636","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138709636?lang=zh_cn&edition=full","pubTime":"2026-02-26 19:04","pubTimestamp":1772103865,"startTime":"0","endTime":"0","summary":"百济神州（Beone Medicines Ltd.）最新披露2025年第四季度及全年财务业绩报告，核心产品百悦泽（Brukinsa）的全球商业化表现成为最大亮点。财报数据充分印证了公司在肿瘤治疗领域奠定的战略性领导地位。\n通过创新疗法与全球化商业布局的双轮驱动，百济神州持续巩固其在肿瘤学领域的核心竞争力。百悦泽作为公司旗舰产品，其销售增长势头显著，为全年营收贡献重要增量。\n这份成绩单不仅反映了公司扎实的研发积累，更展现出其将科学创新转化为全球市场价值的卓越能力。在肿瘤治疗格局加速演进的背景下，百济神州正通过多元化的产品管线与前瞻性战略，持续引领行业创新方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2614015080","title":"百济神州跌5.65% 东莞证券等在其历史最高点唱多","url":"https://stock-news.laohu8.com/highlight/detail?id=2614015080","media":"中国经济网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614015080?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:05","pubTimestamp":1772096700,"startTime":"0","endTime":"0","summary":"中国经济网北京2月26日讯 百济神州(688235.SH)今日收报263.44元，跌幅5.65%。百济神州2025年9月2日盘中股价创下历史高点346.00元。东莞证券股份有限公司研究员谢雄雄2025年9月2日发布研报《 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260226/c674934400.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260226/c674934400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","161027","688235"],"gpt_icon":0},{"id":"2614009264","title":"什么情况？百济神州绩前挫逾6%！港股通创新药ETF（520880）、港股通医疗ETF（159137）跌近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614009264","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614009264?lang=zh_cn&edition=full","pubTime":"2026-02-26 15:01","pubTimestamp":1772089260,"startTime":"0","endTime":"0","summary":"2月26日午后，港股医药股加速走低，创新药产业链跌幅靠前，港股通创新药ETF、港股通医疗ETF华宝双双跌逾2%，场内溢价同步走高，显示“抄底”资金有所行动。 个股方面，权重龙头百济神州跌逾6%居首，据悉，该公司将于今日披露2025年财报。作为创新药领域龙头企业，百济神州为港股通创新药ETF 、港股通医疗ETF华宝持仓股，权重占比分别为11.27%、2.13%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7aeeed2b7873496584fe7f3c4e94617c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-02-26/doc-inhpcqkn4412142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688235","BK4139","LU1251922891.USD","LU1719994722.HKD","BK1583","BK4585","LU0307460666.USD","BK1500","BK1588","BK0239","BK4588","LU2328871848.SGD","LU0588546209.SGD","BK4526","520510","ONC","06160","LU1969619763.USD","159137","BK1161","LU1770034418.SGD","LU1303224171.USD","520880"],"gpt_icon":0},{"id":"2611196267","title":"百济神州皮下注射剂型获临床试验许可，将发布2025年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2611196267","media":"经济观察网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611196267?lang=zh_cn&edition=full","pubTime":"2026-02-14 06:37","pubTimestamp":1771022220,"startTime":"0","endTime":"0","summary":"经济观察网 百济神州近期主要有两大事件值得关注。首先，根据北京药研汇报道，2026年2月10日，百济神州的替雷利珠单抗注射液（皮下注射）临床试验补充申请获得国家药品监督管理局药品审评中 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260214/c674813044.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260214/c674813044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2611290672","title":"百济神州2025年财报发布及电话会议安排公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2611290672","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611290672?lang=zh_cn&edition=full","pubTime":"2026-02-13 06:54","pubTimestamp":1770936840,"startTime":"0","endTime":"0","summary":"经济观察网 百济神州已宣布将于2026年2月26日发布其2025年第四季度及全年财务业绩，并于同日举行电话会议进行业绩发布。公司预计在2026年3月31日或之前发布经审核的2025年年度业绩。业绩经 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260213/c674781472.shtml","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260213/c674781472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688235"],"gpt_icon":0},{"id":"2610990656","title":"百济神州：公司会在定期报告中面向所有投资者统一披露截至相应报告期末的股东户数","url":"https://stock-news.laohu8.com/highlight/detail?id=2610990656","media":"证券日报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610990656?lang=zh_cn&edition=full","pubTime":"2026-02-09 22:05","pubTimestamp":1770645946,"startTime":"0","endTime":"0","summary":"证券日报网讯2月9日，百济神州在互动平台回答投资者提问时表示，公司在已披露的2025年第三季度报告中公布，截至2025年9月30日，公司普通股的登记股东有36164户（其中包括人民币股份登记股东36008户，41户登记在港股股东名册及115户登记在瑞士股东名册的股东）和8户美国存托股份的记录持有人，合计36172户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602093645740228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0588546209.SGD","LU2328871848.SGD","BK1588","ONC","BK4139","LU1770034418.SGD","BK4526","LU1969619763.USD","LU1251922891.USD","BK1583","688235","06160","BK4585","LU1719994722.HKD","BK1161","BK1500","LU0307460666.USD","LU1303224171.USD","BK0239"],"gpt_icon":0},{"id":"2609525212","title":"每周股票复盘：百济神州（688235）1月31日已发行股1,425,622,549股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609525212","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609525212?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:21","pubTimestamp":1770488470,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，百济神州报收于272.5元，较上周的277.26元下跌1.72%。本周，百济神州2月4日盘中最高价报279.9元。本周关注点公司公告汇总：百济神州截至2026年1月31日已发行普通股总数为1,425,622,549股，无库存股。公司公告汇总港股公告：证券变动月报表百济神州有限公司截至2026年1月31日，法定注册股本总额为231,146.38美元，每股面值0.0001美元。人民币股份115,055,260股于科创板上市，股份代号688235。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","06160","LU1303224171.USD","LU0307460666.USD","LU0588546209.SGD","LU1251922891.USD","LU1969619763.USD","BK1161","BK1588","LU2328871848.SGD","LU1770034418.SGD","LU1719994722.HKD","688235","BK0239","BK1500"],"gpt_icon":0},{"id":"2609096517","title":"美股内部交易 | 百济神州于2月6日披露5笔公司内部人交易情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2609096517","media":"同花顺iNews","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609096517?lang=zh_cn&edition=full","pubTime":"2026-02-07 08:00","pubTimestamp":1770422400,"startTime":"0","endTime":"0","summary":"2026年2月6日， 百济神州（ONC）披露5笔公司内部人交易情况。高管Lee Chan Henry于2026年2月4日卖出996股。【近期内部交易】披露日期职位姓名交易日期买/卖数量每股成交价/美元总金额/美元2 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20260207/c674630643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2609309272","title":"百济神州（688235）披露证券变动月报表，2月5日股价下跌0.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609309272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609309272?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:30","pubTimestamp":1770301839,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，百济神州报收于275.6元，较前一交易日下跌0.73%，最新总市值为4246.11亿元。该股当日开盘277.06元，最高279.79元，最低273.13元，成交额达5.45亿元，换手率为1.72%。近日，百济神州有限公司发布证券变动月报表。公告同时确认公众持股量符合上市规则要求，所有证券发行均已获董事会批准并合规进行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1770034418.SGD","161027","BK1500","LU0307460666.USD","06160","BK1583","688235","LU1251922891.USD","BK1161","LU0588546209.SGD","LU1303224171.USD","BK1588","LU1719994722.HKD","BK0239","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2608072455","title":"每周股票复盘：百济神州（688235）授出273,442股普通股受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072455","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608072455?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:43","pubTimestamp":1769881393,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，百济神州报收于277.26元，较上周的289.38元下跌4.19%。本周，百济神州1月29日盘中最高价报292.0元。1月30日盘中最低价报277.12元。百济神州当前最新总市值4271.68亿元，在化学制药板块市值排名1/150，在两市A股市值排名29/5184。授出代价为零，无表现目标及退扣机制。该等单位将在未来四年分批归属，每次归属25%，须持续服务。本次授出后，2016期权及激励计划尚余60,920,391股股份可供授出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0307460666.USD","LU2328871848.SGD","LU1770034418.SGD","BK0239","BK1500","BK1583","BK1588","LU0588546209.SGD","LU1303224171.USD","LU1969619763.USD","LU1719994722.HKD","06160","BK1161","LU1251922891.USD","688235"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772281986319,"stockEarnings":[{"period":"1week","weight":-0.0784},{"period":"1month","weight":-0.1083},{"period":"3month","weight":-0.1105},{"period":"6month","weight":-0.073},{"period":"1year","weight":0.1403},{"period":"ytd","weight":-0.0406}],"compareEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.0028},{"period":"3month","weight":0.0705},{"period":"6month","weight":0.079},{"period":"1year","weight":0.2287},{"period":"ytd","weight":0.0489}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百济神州有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"36008人(较上一季度增加55.74%)","perCapita":"3195股","listingDate":"2021-12-15","address":"c/oBeOneMedicinesIGmbH,Aeschengraben27,4051Basel,Switzerland","registeredCapital":"15万元","survey":" 百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。","listedPrice":192.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,688235,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}